Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban plus aspirin vs aspirin alone after lower extremity revascularization in symptomatic PAD
CTR20160301Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rivaroxaban in arteriosclerosis obliterans, sponsored by Bayer. Started Aug 2016; status: completed.
02
Drugs
rivaroxaban
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on CTR20160301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160301.